⌕
Regeneron Pharmaceuticals · REGN · Nasdaq
Tenet 64 · Solid
Compare
$955.47+0.45%At closeTenet 64 · Solid
$955.47+4.28 (+0.45%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Regeneron Pharmaceuticals (REGN) Stock

Regeneron Pharmaceuticals (REGN) closed at $955.47 on Nov 13, 2026; its Tenet Score is 64 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$955.47
Nov 13, 2026
Market cap
$98.8B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
20.9×
price ÷ earnings
Dividend yield
0.39%
past year's regular dividends ÷ price
52-week range
591.52 – 991.73
low → high
Tenet Score
64/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Regeneron Pharmaceuticals, Inc. scores 64/100. Solid. Strongest on quality and financial health, trading at 21× earnings versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
64/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
58
Quality
69
Health
69
Growth
61

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityCHealthCGrowthCMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
3.0×
price to book value
P/S
5.8×
price to fiscal 2025 sales
ROE
15%
return on equity
Operating margin
24.9%
fiscal 2025, before interest and tax
Net margin
28.5%
of revenue kept
Current ratio
3.35
current assets to liabilities
Net debt / EBITDA
−1.4×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macul…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 392 US ETFs · top wrappers by weightSee all ETFs holding REGN →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

Compare Regeneron Pharmaceuticals with

What sector and industry is Regeneron Pharmaceuticals in?

Regeneron Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Regeneron Pharmaceuticals' Tenet Score?

Regeneron Pharmaceuticals' Tenet Score is 64 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.